IVIXF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EDT
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.04
Previous CloseN/A
Volume10.00
Average Volume (3M)0.00
Market Cap
$3.43M
Enterprise Value$4.97M
Total Cash (Recent Filing)$137.54K
Total Debt (Recent Filing)$627.68K
Price to Earnings (P/E)―
Beta-3.12
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding109,200,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.12
Enterprise Value/Ebitda-0.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt reduces refinancing and interest risks, giving management durable runway to advance clinical R&D and seek partners. Low leverage is a structural strength for a clinical-stage biotech, lowering fixed costs and preserving optionality during multi‑quarter trial timelines.
Focused Clinical-stage Asset (IVX-P02)Concentrating resources on a single, differentiated PDT asset targeting oncology (breast and GI) creates focused scientific expertise and clearer regulatory pathways. A specialized modality can build durable competitive barriers and make the program more partnerable if clinical signals appear.
Partnering Commercialisation RouteAn explicit strategy to pursue partner-led commercialization reduces the capital intensity and operational burden for a small biotech. Structurally this enables access to external development, regulatory and commercial capabilities, helping progress programs without full internal scale-up.
Bears Say
Zero Revenue & Widening LossesA shift to zero reported revenue and a materially larger net loss is a durable red flag: it erodes internal funding capacity and indicates programs are not yet revenue-generating. Continued losses make execution dependent on external capital or milestone-based partner funding over coming quarters.
Shrinking Equity And AssetsA marked decline in shareholders' equity and total assets reduces financial cushions and flexibility to fund trials or absorb setbacks. Structurally this increases the probability of dilution or constrained program timelines if partner funding or capital raises are delayed.
Persistent Negative Cash GenerationRepeated negative operating and free cash flows mean the business structurally relies on external financing to sustain R&D. This dependence raises execution risk for clinical programs and could delay trials or force dilutive funding rounds absent firm partnership commitments.
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was $0.04 and its highest was $0.04 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is $3.43M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 29 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.029.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 109,200,640 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in IVIXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―